Merck: positive results on advanced melanoma
(CercleFinance.com) - A phase 3 trial showed the potential for Keytruda to significantly prolong the time before the disease recurs in patients with high-risk melanoma, Merck said on Monday.
Merck's anti-PD-1 therapy significantly improved recurrence-free survival compared to placebo as adjuvant therapy in patients with stage 3 resected high-risk melanoma, the group said.
The study will now continue so as to evaluate other key endpoints, including overall survival.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Merck's anti-PD-1 therapy significantly improved recurrence-free survival compared to placebo as adjuvant therapy in patients with stage 3 resected high-risk melanoma, the group said.
The study will now continue so as to evaluate other key endpoints, including overall survival.
Copyright (c) 2018 CercleFinance.com. All rights reserved.